Glycominds International - the leading provider of digestive disease solutions
About Glycominds International
For more than 15 years, Glycominds has been a leading groundbreaker in microbiome biomarker research, offering the only validated serum biomarker tests on the market for Inflammatory Bowel Disease. Our laboratories produce results from a strong and proprietary technology platform, providing answers to physicians and allowing many patients to benefit from personalized control over their diagnosis and/or progression of their disease.
Glycominds international, an innovative diagnostics company, develops and commercializes gastrointestinal disease management tools and services. Our GI dry serum testing allow physicians to help identify patients who have Celiac Disease and Inflammatory Bowel Diseases (mainly Crohns Disease and Ulcerative Colitis) to achieve early, non-invasive, accurate and cost-effective diagnosis, predict Crohns Disease patients at a higher risk for more complicated disease, as well as monitoring Anti-TNF therapy.